Joanne Lancaster, VP of Project Team Development at NGM Biopharmaceuticals, presents on NGM120, a GFRAL antagonist antibody intended for the investigation of safety, tolerability, and efficacy in hyperemesis gravidarum. Lancaster elaborates on the preclinical data, clinical study design, and the potential of NGM120 to address severe nausea and vomiting in pregnancy. She also details the EMERALD study, which is set to launch in both Australia and the United Kingdom, focusing on the antibody's action mechanism, safety assessments, and efficacy endpoints. Audience members pose insightful questions, fostering a robust discussion on the implications and potential challenges of the study.

Please Note: The small fee will help cover the platform fee for the video hosting. Your purchase directly supports the HER Foundation's vital work. If you wish to contribute a larger amount, please consider donating directly on our official website (hyperemesis.org/donate). Direct donations ensure a significantly higher percentage of your contribution goes directly to our programs.

NGM120, a GFRAL Antagonist Antibody, for Investigation of Safety, Tolerability and Efficacy in Hyperemesis Gravidarum presented by Joanne Lancaster, PhD at the International Colloquium of Hyperemesis Gravidarum (ICHG) 2024 conference in Ventura, California.